Literature DB >> 20367572

Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.

Jessica A Shafer1, Conrad R Cruz, Ann M Leen, Stephanie Ku, An Lu, Alexandra Rousseau, Helen E Heslop, Cliona M Rooney, Catherine M Bollard, Aaron E Foster.   

Abstract

Side-population (SP) analysis has been used to identify progenitor cells from normal and malignant tissues as well as revealing tumor cells with increased resistance to radiation and chemotherapy. Despite enhanced chemoresistance, tumor SP cells may still express tumor-associated antigens (TAAs), which may render them susceptible to elimination by the immune system. In this study, we show that both Hodgkin lymphoma (HL) cell lines and primary HL tumor samples contain a distinct SP phenotype. Importantly, while these cells showed increased resistance to gemcitabine, a commonly used drug for the treatment of refractory HL, HL SP cells also expressed higher levels of the TAAs MAGEA4, SSX2, survivin, and NY-ESO-1, which allowed them to be specifically recognized and killed by TAA-specific cytotoxic T lymphocytes. This study suggests that chemoresistant HL SP cells can be targeted by the immune system, providing a rationale for combined chemotherapy and immunotherapy for the treatment of HL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367572      PMCID: PMC2991134          DOI: 10.3109/10428191003713968

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  51 in total

1.  Expression of gene MAGE-A4 in Reed-Sternberg cells.

Authors:  H Chambost; N Van Baren; F Brasseur; D Godelaine; L Xerri; S J Landi; I Theate; J Plumas; G C Spagnoli; G Michel; P G Coulie; D Olive
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

2.  Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.

Authors:  P L Zinzani; M Bendandi; V Stefoni; P Albertini; F Gherlinzoni; M Tani; P P Piccaluga; S Tura
Journal:  Haematologica       Date:  2000-09       Impact factor: 9.941

Review 3.  The Reed-Sternberg cell in classical Hodgkin's disease.

Authors:  W C Chan
Journal:  Hematol Oncol       Date:  2001-03       Impact factor: 5.271

4.  An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Authors:  S Gottschalk; C Y Ng; M Perez; C A Smith; C Sample; M K Brenner; H E Heslop; C M Rooney
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

5.  Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.

Authors:  J Gong; V Apostolopoulos; D Chen; H Chen; S Koido; S J Gendler; I F McKenzie; D Kufe
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

6.  A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.

Authors:  G G Wulf; R Y Wang; I Kuehnle; D Weidner; F Marini; M K Brenner; M Andreeff; M A Goodell
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

7.  Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.

Authors:  A Santoro; H Bredenfeld; L Devizzi; H Tesch; V Bonfante; S Viviani; F Fiedler; H S Parra; C Benoehr; M Pacini; G Bonadonna; V Diehl
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

8.  Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

Authors:  Luca Sigalotti; Elisabetta Fratta; Sandra Coral; Silvia Tanzarella; Riccardo Danielli; Francesca Colizzi; Ester Fonsatti; Catia Traversari; Maresa Altomonte; Michele Maio
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

9.  Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation.

Authors:  E Bedner; P Smolewski; P Amstad; Z Darzynkiewicz
Journal:  Exp Cell Res       Date:  2000-08-25       Impact factor: 3.905

10.  Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.

Authors:  Lothar Hambach; Kam-Wing Ling; Jos Pool; Zohara Aghai; Els Blokland; Hans J Tanke; Jan A Bruijn; Hans Halfwerk; Hester van Boven; Brigitte Wieles; Els Goulmy
Journal:  Blood       Date:  2008-12-18       Impact factor: 22.113

View more
  20 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

2.  Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.

Authors:  Benjamin Rengstl; Frederike Schmid; Christian Weiser; Claudia Döring; Tim Heinrich; Kathrin Warner; Petra S A Becker; Robin Wistinghausen; Sima Kameh-Var; Eva Werling; Arne Billmeier; Christian Seidl; Sylvia Hartmann; Hinrich Abken; Ralf Küppers; Martin-Leo Hansmann; Sebastian Newrzela
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

Review 3.  Hodgkin lymphoma.

Authors:  Ralf Küppers; Andreas Engert; Martin-Leo Hansmann
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 4.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 5.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Authors:  Ulrike Gerdemann; Usha Katari; Anne S Christin; Conrad R Cruz; Tamara Tripic; Alexandra Rousseau; Stephen M Gottschalk; Barbara Savoldo; Juan F Vera; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2011-09-13       Impact factor: 11.454

7.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

Review 8.  Therapeutic cancer vaccines in combination with conventional therapy.

Authors:  Mads Hald Andersen; Niels Junker; Eva Ellebaek; Inge Marie Svane; Per Thor Straten
Journal:  J Biomed Biotechnol       Date:  2010-06-29

9.  Flow cytometric detection of the classical hodgkin lymphoma: clinical and research applications.

Authors:  Mikhail Roshal; Brent L Wood; Jonathan R Fromm
Journal:  Adv Hematol       Date:  2010-11-28

10.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.